Biopolym. Cell. 2014; 30(5):372-376.
http://dx.doi.org/10.7124/bc.0008B4
Bioorganic Chemistry
Toxic effect of C60 fullerene-doxorubicin complex towards tumor and normal cells in vitro
1Prylutska S. V., 2Didenko G. V., 2Potebnya G. P., 1Bogutska K. I., 1Prylutskyy Yu. I., 3Ritter U., 3Scharff P.
  1. Educational and Scientific Center "Institute of Biology",
    Taras Shevchenko National University of Kyiv
    64/13, Volodymyrska Str., Kyiv, Ukraine, 01601
  2. R. E. Kavetsky Institute of Experimental Pathology, Oncology and Radiobiology, NAS of Ukraine
    45, Vasilkivska Str., Kyiv, Ukraine, 03022
  3. Institute of Chemistry and Biotechnology,
    Technical University of Ilmenau
    25, Weimarer Str., Ilmenau, Germany, 98693

Abstract

Creation of new nanostructures possessing high antitumor activity is an important problem of modern biotechnology. Aim. To evaluate cytotoxicity of created complex of pristine C60 fullerene with the anthracycline antibiotic doxorubicin (Dox), as well as of free C60 fullerene and Dox, towards different cell types – tumor, normal immunocompetent and hepatocytes. Methods. Measurement of size distribution for particles in C60 + Dox mixture was performed by a dynamic light scattering (DLS) technique. Toxic effect of C60 + Dox complex in vitro towards tumor and normal cells was studied using the MTT assay. Results. DLS experiment demonstrated that the main fraction of the particles in C60 + Dox mixture had a diameter in the range of about 132 nm. The toxic effect of C60 + Dox complex towards normal (lymphocytes, macrophages, hepatocytes) and tumor (Ehrlich ascites carcinoma, leukemia L1210, Lewis lung carcinoma) cells was decreased by ~10–16 % and ~7–9 %, accordingly, compared with the same effect of free Dox. Conclusions. The created C60 + Dox composite may be considered as a new pharmacological agent that kills effectively tumor cells in vitro and simultaneously prevents a toxic effect of the free form of Dox on normal cells.
Keywords: С60 fullerene-doxorubicin complex, normal and tumor cells, cytotoxicity, MTT assay, dynamic light scattering
Full text: (PDF, in English)

References

[1] Anilkumar P, Lu F, Cao L, Luo PG, Liu JH, Sahu S, Tackett KN, Wang Y, Sun YP. Fullerenes for applications in biology and medicine. Curr Med Chem. 2011;18(14):2045-59.
[2] Darwish AD. Fullerenes. Annu Rep Prog Chem, Sect A: Inorg Chem. 2012;108:464–77.
[3] Gharbi N, Pressac M, Hadchouel M, Szwarc H, Wilson SR, Moussa F. [60]fullerene is a powerful antioxidant in vivo with no acute or subacute toxicity. Nano Lett. 2005;5(12):2578-85.
[4] Prylutska SV, Grynyuk II, Matyshevska OP, Prylutskyy YI, Ritter U, Scharff P. Anti?oxidant Properties of C 60 Fullerenes in vitro . Fullerenes Nanotubes Carbon Nanostruct. 2008;16(5-6):698–705.
[5] Scharff P, Ritter U, Matyshevska OP, Prylutska SV, Grynyuk II, Golub AA, Prylutskyy YI, Burlaka AP. Therapeutic reactive oxygen generation. Tumori. 2008;94(2):278-83.
[6] Schuetze C, Ritter U, Scharff P, Fernekorn U, Prylutska S, Bychko A, et al. Interaction of N-fluorescein5-isothiocyanate pyrrolidine-C60 compound with a model bimolecular lipid membrane. Mater Sci Engineer C. 2011; 31(5): 1148–50.
[7] Prylutska S, Bilyy R, Overchuk M, Bychko A, Andreichenko K, Stoika R, Rybalchenko V, Prylutskyy Y, Tsierkezos NG, Ritter U. Water-soluble pristine fullerenes C60 increase the specific conductivity and capacity of lipid model membrane and form the channels in cellular plasma membrane. J Biomed Nanotechnol. 2012;8(3):522-7.
[8] Prylutska SV, Burlaka AP, Klymenko PP, Grynyuk II, Prylutskyy YI, Sch?tze C, et al. Using water-soluble C60 fullerenes in anticancer therapy. Cancer Nano. 2011;2(1-6):105–10.
[9] Prylutska SV, Burlaka AP, Prylutskyy YI, Ritter U, Scharff P. Pristine C(60) fullerenes inhibit the rate of tumor growth and metastasis. Exp Oncol. 2011;33(3):162-4.
[10] Lucaf? M, Pelillo C, Carini M, Da Ros T, Prato M, Sava G. A Cationic [60] Fullerene Derivative Reduces Invasion and Migration of HT-29 CRC Cells in Vitro at Dose Free of Significant Effects on Cell Survival. Nano-Micro Letters. 2014;6(2):163–8.
[11] Aschberger K, Johnston HJ, Stone V, Aitken RJ, Tran CL, Hankin SM, Peters SA, Christensen FM. Review of fullerene toxicity and exposure--appraisal of a human health risk assessment, based on open literature. Regul Toxicol Pharmacol. 2010;58(3):455-73.
[12] Andrievsky G, Klochkov V, Derevyanchenko L. Is the C 60 Fullerene Molecule Toxic?! . Fullerenes Nanotubes Carbon Nanostruct. 2005;13(4):363–76.
[13] Prylutska SV, Grynyuk II, Grebinyk SM, Matyshevska OP, Prylutskyy YI, Ritter U, et al. Comparative study of biological action of fullerenes C 60 and carbon nanotubes in thymus cells . Matewiss u Werkstofftech. 2009;40(4):238–41.
[14] Rouse JG, Yang J, Barron AR, Monteiro-Riviere NA. Fullerene-based amino acid nanoparticle interactions with human epidermal keratinocytes. Toxicol In Vitro. 2006;20(8):1313-20.
[15] Hrelia S, Fiorentini D, Maraldi T, Angeloni C, Bordoni A, Biagi PL, Hakim G. Doxorubicin induces early lipid peroxidation associated with changes in glucose transport in cultured cardiomyocytes. Biochim Biophys Acta. 2002;1567(1-2):150-6.
[16] Menna P, Paz OG, Chello M, Covino E, Salvatorelli E, Minotti G. Anthracycline cardiotoxicity. Expert Opin Drug Saf. 2012;11 Suppl 1:S21-36.
[17] Injac R, Perse M, Cerne M, Potocnik N, Radic N, Govedarica B, Djordjevic A, Cerar A, Strukelj B. Protective effects of fullerenol C60(OH)24 against doxorubicin-induced cardiotoxicity and hepatotoxicity in rats with colorectal cancer. Biomaterials. 2009;30(6):1184-96.
[18] Evstigneev MP, Buchelnikov AS, Voronin DP, Rubin YV, Belous LF, Prylutskyy YI, Ritter U. Complexation of C60 fullerene with aromatic drugs. Chem phys chem. 2013;14(3):568-78.
[19] Liu JH, Cao L, Luo PG, Yang ST, Lu F, Wang H, Meziani MJ, Haque SA, Liu Y, Lacher S, Sun YP. Fullerene-conjugated doxorubicin in cells. ACS Appl Mater Interfaces. 2010;2(5):1384-9.
[20] Skamrova GB, Laponogov I, Buchelnikov AS, Shckorbatov YG, Prylutska SV, Ritter U, Prylutskyy YI, Evstigneev MP. Interceptor effect of C60 fullerene on the in vitro action of aromatic drug molecules. Eur Biophys J. 2014;43(6-7):265-76.
[21] Prylutskyy YI, Petrenko VI, Ivankov OI, Kyzyma OA, Bulavin LA, Litsis OO, Evstigneev MP, Cherepanov VV, Naumovets AG, Ritter U. On the origin of C?? fullerene solubility in aqueous solution. Langmuir. 2014;30(14):3967-70.
[22] Ritter U, Prylutskyy YI, Evstigneev MP, Davidenko NA, Cherepanov VV, Senenko AI, et al. Structural Features of Highly Stable Reproducible C 60 Fullerene Aqueous Colloid Solution Probed by Various Techniques . Fullerenes, Nanotubes and Carbon Nanostructures. 2014;23(6):530–4.
[23] Prylutskyy YI, Buchelnikov AS, Voronin DP, Kostjukov VV, Ritter U, Parkinson JA, Evstigneev MP. C60 fullerene aggregation in aqueous solution. Phys Chem Chem Phys. 2013;15(23):9351-60.
[24] Sashchenko LP, Lukyanova TI, Kabanova OD, Mirkina I, Yatskin ON, Pongor S, Gnuchev NV. Different pathways of the release of cytotoxic proteins in LAK cells. Immunol Lett. 1996;53(1):25-9.
[25] Carmichael J, Mitchell JB, DeGraff WG, Gamson J, Gazdar AF, Johnson BE, Glatstein E, Minna JD. Chemosensitivity testing of human lung cancer cell lines using the MTT assay. Br J Cancer. 1988;57(6):540-7.